Unlock instant, AI-driven research and patent intelligence for your innovation.

Low-polarity rare ginsenoside mixture and use thereof

A ginsenoside, low polarity technology, applied in the field of medicine, can solve the problem of not showing anti-tumor activity and the like

Pending Publication Date: 2019-09-17
SHENZHEN YINUO BIOPHARM CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, it has been found that there are more than 60 prototype ginsenosides in Araliaceae plants, which can be divided into two categories: 1) diol group ginsenosides (Ra, Rb1, Rb2, Rb3, Rc, Rd, etc.); 2) triol group ginsenosides. Ginsenosides (Re, Rf, Rg1, Rg2, Rh1, etc.) are all composed of aglycone and sugar, and are usually soluble in water. and learning ability, anti-aging, calming the nerves, etc., but did not show obvious anti-tumor activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Low-polarity rare ginsenoside mixture and use thereof
  • Low-polarity rare ginsenoside mixture and use thereof
  • Low-polarity rare ginsenoside mixture and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1: Low polarity rare ginsenoside Δ(20-21)PPT / Δ(20-22)PPT mixture and its preparation method

[0070] This embodiment provides a low-polarity rare ginsenoside Δ(20-21)PPT / Δ(20-22)PPT mixture, which consists of

[0071]

[0072] Low polarity rare ginsenoside monomer Δ(20-21)PPT and has the following structural formula

[0073]

[0074] The low-polarity rare ginsenoside monomer Δ(20-22)PPT is mixed at a weight ratio of 7:1; 1:5; 1:2 and 1:3.

[0075] The specific preparation method is as follows:

[0076] (1) Weigh 8.75mg low polarity rare ginsenoside monomer Δ(20-21)PPT (provided by Canada Royal Enoch Phytomedicine Ltd) and 1.25mg low polarity rare ginsenoside monomer Δ( 20-22) PPT (provided by Canada Royal Enoch Phytomedicine Ltd), mixed uniformly in a ratio of 7:1 by weight to obtain low polarity rare ginsenoside Δ(20-21)PPT / Δ(20 -22) PPT mixture (7:1).

[0077] (2) Weigh 1.67mg of low polarity rare ginsenoside monomer Δ(20-21)PPT (provided by Canada R...

Embodiment 2

[0080] Example 2: In vitro inhibition of multi-type tumor cell proliferation by low-polarity rare ginsenoside Δ(20-21)PPT / Δ(20-22)PPT mixture in different mixing ratios

[0081] Experimental sample:

[0082] Test drug: the first three ratios of low polarity rare ginsenoside Δ(20-21)PPT / Δ(20-22)PPT mixture prepared in Example 1.

[0083] Control drug: paclitaxel (SELLECK; Cat.#S1150); low-polarity rare ginsenoside monomer Rg3 (purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number B21059); low-polarity rare ginsenoside monomer Δ(20 -21) PPT (from Example 1); low polarity rare ginsenoside monomer Δ(20-22) PPT (from Example 1).

[0084] Experimental steps:

[0085] 18 cell lines (including 17 tumor cell lines and 1 human umbilical vein endothelial cell line) were used as experimental cell lines, and cells in logarithmic growth phase (3×10 4 / mL to 2.5×10 5 / mL), inoculated in a 96-well plate with 100 μL per well, one 96-well plate for each cell line; then take...

Embodiment 3

[0106] Example 3: Δ(20-21)PPT / Δ(20-22)PPT(1:3) regulation of cell cycle distribution experiment

[0107] Experimental sample:

[0108] Low polarity rare ginsenoside Δ(20-21)PPT / Δ(20-22)PPT mixture (1:3) prepared in Example 1;

[0109] Experimental steps:

[0110] Use non-small cell lung cancer cell A549 as the cell line used in the experiment, inoculate 5000 cells per well in a 96-well plate, and place it in a cell culture incubator to culture and adhere to the wall overnight; then, add Tecan D300e digital dispenser to the A549 cells in the 96-well plate The final concentration in the wells of the plate is 32μM, 64μM, 128μM, 192μM (that is, Δ(20-21)PPT / Δ(20-22)PPT(1:3) acts on A549 cells for 72 hours and 1 times the IC50 value of inhibiting the proliferation of the cells , 2-fold, 4-fold, and 6-fold concentrations) of the test drug Δ(20-21)PPT / Δ(20-22)PPT (1:3). The test drug was dissolved in DMSO solution, and two duplicate holes were set up for each concentration. The fin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and relates to a low-polarity rare ginsenoside delta(20-21)PPT / delta(20-22)PPT mixture and use thereof to preparation of medicines and / or health-care products for treating and / or preventing tumor and / or cancer, and the use of the low-polarity rare ginsenoside delta(20-21)PPT / delta(20-22)PPT mixture to preparation of medicines and / or health-care products for adjusting immunity, improving microcirculation and increasing the quality of life. The invention further provides a composition including the low-polarity rare ginsenoside delta(20-21)PPT / delta(20-22)PPT mixture and the use of the composition.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a class of low-polarity rare ginsenoside mixture and its application, as well as its pharmacological mechanism in antitumor. Background technique [0002] Cancer is the second largest disease in the world that ravages human life, and its mortality rate is second only to cardiovascular and cerebrovascular diseases, and it is one of the most important factors of human death. The latest edition of the "World Cancer Report" in charge of the International Cancer Research Center (IARC), the official cancer agency under the WHO, predicts that global cancer cases will show a rapid increase, from 14 million in 2012 to 19 million people in 2025, will reach 24 million people by 2035. The report also shows that in 2012, nearly half of the new cancer cases in the world occurred in Asia, most of which were in China, and China ranked first in the number of new cancer cases. In 2012, there were 3.07 mi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P35/00A61P35/02A23L33/11
CPCA61K31/575A61P35/00A61P35/02A23L33/11A23V2002/00A23V2200/308A23V2200/324A23V2250/2124A23V2250/2136
Inventor 余佩华邓跃敏
Owner SHENZHEN YINUO BIOPHARM CO LTD